Achillion Pharmaceuticals Inc. (ACHN) Announces Lead Candidate for Hepatitis C Treatment
The hepatitis C virus (HCV), the most common cause of viral hepatitis, results in inflammation of the liver. The American Association of Liver Disease estimates that more than 170 million people are infected with HCV around the world; without proper treatment, chronic hepatitis can lead to permanent liver damage, including liver failure or death. Despite the statistics, there are currently only few options available for treatment of HCV infection. Achillion Pharmaceuticals Inc. focuses on developing treatments for patients with infectious diseases such as HCV, resistant bacterial infections and HIV. The company today announced its nomination of ACH-2684 as the lead…